Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ayrmid
Ireland
- Ownership
- Private
- Development stage
- Other
01
Overview
Ayrmid, via its subsidiary Gamida Cell, has FDA approval for Omisirge (omidubicel-onlv) for hematologic malignancies, and holds commercial rights (ex-Asia) for motixafortide (APHEXDA), an FDA-approved stem cell mobilizer for autologous transplantation in multiple myeloma. It is pursuing a new indication for omidubicel in severe aplastic anemia (sBLA with FDA priority review).
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell therapySynthetic peptideSmall molecule
- Industry
- Biotech
02
Partnerships
RoslinCT
Beyond the preview
Go deeper on Ayrmid.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ayrmid.